Asciminib: a new therapeutic option in chronic-phase CML with treatment failure.

Yeung, David T; Shanmuganathan, Naranie; Hughes, Timothy P

Yeung, David T; Shanmuganathan, Naranie; Hughes, Timothy P.

Affiliation

Yeung DT; Precision Medicine Theme, South Australian Health and Medical Research Institute, Adelaide, Australia.
Shanmuganathan N; Adelaide Medical School, University of Adelaide, Adelaide, Australia; and.
Hughes TP; Haematology Department, Royal Adelaide Hospital, Adelaide, Australia.

Blood ; 139(24): 3474-3479, 2022 06 16.

Article in En | MEDLINE | ID: mdl-35468180

Subject(s)

Antineoplastic Agents; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Chronic-Phase; Antineoplastic Agents/pharmacology; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl/genetics; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive/drug therapy; Leukemia, Myelogenous, Chronic, BCR-ABL Positive/genetics; Leukemia, Myeloid, Chronic-Phase/drug therapy; Mutation; Niacinamide/analogs & derivatives; Protein Kinase Inhibitors/pharmacology; Protein Kinase Inhibitors/therapeutic use; Pyrazoles; Treatment Failure

Fulltext

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Leukemia, Myeloid, Chronic-Phase / Antineoplastic Agents Limits: Humans Language: En Journal: Blood Year: 2022 Type: Article Affiliation country: Australia

Fulltext

XML

PubMed Links

Search on Google